Taiwanese Journal of Obstetrics and Gynecology
Volume 46, Issue 2 , Pages 121-126, June 2007

Effects of Tibolone on the Breast of Postmenopausal Women

Department of Obstetrics and Gynecology, Taipei Veteran General Hospital, and National Yang-Ming University School of Medicine, Taipei, Taiwan

Accepted 23 November 2006.

Article Outline

Summary 

For decades, hormone therapy (HT) has been the mainstay for managing menopausal symptoms. However, the prolonged use of either single estrogen therapy (ET) or a combination therapy of estrogen and progestogen (EPT) might be associated with a slightly increased risk of breast cancer. Alternative therapies that are effective in the prevention and/or treatment of menopause, having associated morbidities but no unwanted effects, are of primary interest in clinical practice. Tibolone (Livial; NV Organon, Oss, The Netherlands) is structurally related to 19-nortestosterone derivatives and is a new postmenopausal regimen with a unique pharmacological profile, licensed for the relief of climacteric symptoms and the prevention of osteoporosis in postmenopausal women. Tibolone exhibits weak estrogenic, progestogenic, and androgenic activities, which in theory might influence the breast. The effect of tibolone on breast tissue, however, is obscure. The purpose of this study was to assess the effects of tibolone on breast safety, and the collected data include preclinical models, clinical observation, and epidemiologic study. Although in vitro studies showed conflicting results (with the majority being favorable effects) regarding the effects of tibolone on breast cells, in vivo studies showed favorable effects of tibolone on the breast in animal models. Similarly, an epidemiologic study indicated an increased risk of breast cancer when tibolone was used to manage climacteric symptoms of postmenopausal women, but accumulated data obtained from radiologic studies (mammography) showed a possible protective effect of tibolone on the breast. Taken together, we conclude that tibolone, if not superior to conventional HT, may be more acceptable to clinicians as a therapeutic drug option for use with symptomatic menopausal women. Only time will tell whether tibolone will be the preferred option.

Key Words:  breast cancer , estrogen , hormone therapy , progestogen , tibolone

No full text is available. To read the body of this article, please view the PDF online.

 

Back to Article Outline

References 

  1. Practice Committee of the American Society for Reproductive Medicine  . Estrogen and progestogen therapy in post-menopausal women . Fertil Steril . 2006;86(Suppl 4):S75–S88
  2. Chao KC, Wang PH, Yen MS, Chang CY, Juang CM, Twu NF, et al. New selective tissue estrogenic activity regulator (STEAR) in menopausal therapy in Taiwan . Taiwan J Obstet Gynecol . 2005;44:327–331
  3. ESHRE Capri Workshop Group  . Hormones and breast cancer . Hum Reprod Update . 2004;10:281–293
  4. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer . Lancet . 1997;350:1047–1059
  5. Collins JA , Blake JM , Crosignani PG . Breast cancer risk with postmenopausal hormonal treatment . Hum Reprod Update . 2005;11:545–560
  6. Cherry N , Gilmour K , Hannaford P , et al.   for The ESPRIT Team. Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial . Lancet . 2002;360:2001–2008
  7. Hodis HN , Mack WJ , Azen SP , et al.   for the Women's Estrogen–Progestin Lipid-Lowering Hormone Atherosclerosis Regression Trial Research Group. Hormone therapy and the progression of coronary-artery atherosclerosis in post-menopausal women . N Engl J Med . 2003;349:535–545
  8. Viscoli CM , Brass LM , Kernan WN , Sarrel PM , Suissa S , Horwitz RI . A clinical trial of estrogen-replacement therapy after ischemic stroke . N Engl J Med . 2001;345:1243–1249
  9. Stefanick ML , Anderson GL , Margolis KL , et al.   Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy . JAMA . 2006;295:1647–1657
  10. Nachtigall LE , Nachtigall RH , Nachtigall RD , Beckman EM . Estrogen replacement therapy II: a prospective study in the relationship to carcinoma and cardiovascular and metabolic problems . Obstet Gynecol . 1979;54:74–78
  11. Angerer P , Stork S , Kothny W , Schmitt P , von Schacky C . Effect of oral postmenopausal hormone replacement on progression of atherosclerosis: a randomized, controlled trial . Arterioscler Thromb Vasc Biol . 2001;21:262–268
  12. Hulley S , Furberg C , Barrett-Connor E , et al.   Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II) . JAMA . 2002;288:58–66
  13. Chlebowski RT , Hendrix SL , Langer RD , et al.   Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: The Women's Health Initiative Randomized Trial . JAMA . 2003;289:3243–3253
  14. Writing Group for the Women's Health Initiative Investigators  . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial . JAMA . 2002;288:321–333
  15. Beral V  for Million Women Study Collaborators . Breast cancer and hormone-replacement therapy in the Million Women Study . Lancet . 2003;362:419–427
  16. Sadarangani A , Salgado AM , Kato S , et al.   In vivo and in vitro estrogenic and progestagenic actions of tibolone . Biol Res . 2005;38:245–258
  17. Kloosterboer HJ . Tissue-selectivity: the mechanism of action of tibolone . Maturitas . 2004;48(Suppl 1):S30–S40
  18. Kloosterboer HJ , Ederveen AG . Pros and cons of existing treatment modalities in osteoporosis: a comparison between tibolone, SERMs and estrogen (± progestogene) treatments . J Steroid Biochem Mol Biol . 2002;83:157–165
  19. Kloosterboer HJ . Tibolone: a steroid with a tissue-specific mode of action . J Steroid Biochem Mol Biol . 2001;76:231–238
  20. Lindsay R , Hart DM , Kraszewski A . Prospective double-blind trial of synthetic steroid (Org OD 14) for preventing postmenopausal osteoporosis . Br Med J . 1980;280:1207–1209
  21. Bruce D , Robinson J , McWilliams S , Reddy M , Fentiman I , Rymer J . Long-term effects of tibolone on mammographic density . Fertil Steril . 2004;82:1343–1347
  22. Berning B , Bennink HJ , Fauser BC . Tibolone and its effects on bone: a review . Climacteric . 2001;4:120–136
  23. Laan E , van Lunsen RH , Everaerd W . The effects of tibolone on vaginal blood flow, sexual desire and arousability in postmenopausal women . Climacteric . 2001;4:28–41
  24. Nathorst-Boos J , Hammar M . Effect on sexual life—a comparison between tibolone and a continuous estradiolnorethisterone acetate regimen . Maturitas . 1997;26:15–20
  25. Castelo-Branco C , Vicente JJ , Figueras F , et al.   Comparative effects of estrogens plus androgens and tibolone on bone, lipid pattern and sexuality in postmenopausal women . Maturitas . 2000;34:161–168
  26. Rymer J , Robinson J , Fogelman I . Ten years of treatment with tibolone 2.5 mg daily: effects on bone loss in post-menopausal women . Climacteric . 2002;5:390–398
  27. Chetrite G , Kloosterboer HJ , Pasqualini JR . Effect of tibolone (Org OD14) and its metabolites on estrone sulphatase activity in MCF-7 and T-47D mammary cancer cells . Anticancer Res . 1997;17:135–140
  28. Gompel A , Siromachkova M , Lombet A , Kloosterboer HJ , Rostene W . Tibolone actions on normal and breast cancer cells . Eur J Cancer . 2000;36(Suppl 4):S76–S77
  29. Gompel A , Chaouat M , Jacob D , Perrot JY , Kloosterboer HJ , Rostene W . In vitro studies of tibolone in breast cells . Fertil Steril . 2002;78:351–359
  30. Kloosterboer HJ , Schoonen WG , Deckers GH , Klijn JG . Effects of progestagens and Org OD14 in in vitro and in vivo tumor models . J Steroid Biochem Mol Biol . 1994;49:311–318
  31. Schoonen WG , Deckers GH , de Gooijer ME , de Ries R , Kloosterboer HJ . Hormonal properties of norethisterone, 7a-methyl-norethisterone and their derivatives . J Steroid Biochem Mol Biol . 2000;74:213–222
  32. de Gooyer ME , Kleyn GT , Smits KC , Ederveen AG , Verheul HA , Kloosterboer HJ . Tibolone: a compound with tissue specific inhibitory effects on sulfatase . Mol Cell Endocrinol . 2001;183:55–62
  33. Kandouz M , Lombet A , Perrot JY , et al.   Proapoptotic effects of antiestrogens, progestins and androgen in breast cancer cells . J Steroid Biochem Mol Biol . 1999;69:463–471
  34. Deckers GH , Verheul HA , van Aalst GB , Cremers EA , de Gooyer ME , Kloosterboer HJ . Tibolone and 5a-dihydrotestosterone alone or in combination with an antiandrogen in a rat breast tumour model . Eur J Cancer . 2002;38:443–448
  35. Mueck AO , Lippert C , Seeger H , Wallwiener D . Effects of tibolone on human breast cancer cells and human vascular coronary cells . Arch Gynecol Obstet . 2003;267:139–144
  36. Kloosterboer HJ . Tissue-selective effects of tibolone on the breast . Maturitas . 2004;49:S5–S15
  37. de Gooyer ME , Deckers GH , Schoonen WG , Verheul HA , Kloosterboer HJ . Receptor profiling and endocrine interactions of tibolone . Steroids . 2003;68:21–30
  38. Cline JM , Register TC , Clarkson TB . Effects of tibolone and hormone replacement therapy on the breast of cynomolgus monkeys . Menopause . 2002;9:422–429
  39. Valdivia I , Campodonico I , Tapia A , Capetillo M , Espinoza A , Lavín P . Effects of tibolone and continuous combined hormone therapy on mammographic breast density and breast histochemical markers in postmenopausal women . Fertil Steril . 2004;81:617–623
  40. Huber J, Palacios S, Berglund L, Hanggi W, Sathanandan SM, Christau S, et al. Effects of tibolone and continuous combined hormone replacement therapy on bleeding rates, quality of life and tolerability in postmenopausal women . BJOG . 2002;109:886–893
  41. Palomba S , Di Carlo C , Morelli M , et al.   Effect of tibolone on breast symptoms resulting from postmenopausal hormone replacement therapy . Maturitas . 2003;45:267–273
  42. Lundstrom E , Christow A , Kersemaekers W , et al.   Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density . Am J Obstet Gynecol . 2002;186:717–722
  43. Valdivia I , Ortega D . Mammographic density in post-menopausal women treated with tibolone, estriol or conventional hormone replacement therapy . Clin Drug Invest . 2000;20:101–107
  44. Egarter C , Eppel W , Vogel S , Wolf G . A pilot study of hormone replacement therapy with tibolone in women with mastopathic breasts . Maturitas . 2001;40:165–171
  45. Bundred NJ , Turner LE . Postmenopausal hormone therapy before and after breast cancer: clinical experiences . Maturitas . 2004;49:S22–S31
  46. Dimitrakakis C , Keramopoulos D , Vourli G , Gaki V , Bredakis N , Keramopoulos A . Clinical effects of tibolone in postmenopausal women after 5 years of tamoxifen therapy for breast cancer . Climacteric . 2005;8:342–351
  47. Kroiss R , Fentiman IS , Helmond FA , et al.   The effect of tibolone in postmenopausal women receiving tamoxifen after surgery for breast cancer: a randomised, double-blind, placebo-controlled trial . BJOG . 2005;112:228–233
  48. Moore RA . Livial: a review of clinical studies . Br J Obstet Gynaecol . 1999;106(Suppl 19):1–21
  49. Gulseren L , Kalafat D , Mandaci H , Gulseren S , Camli L . Effects of tibolone on the quality of life, anxiety-depression levels and cognitive functions in natural menopause: an observational follow-up study . Aust NZ J Obstet Gynaecol . 2005;45:71–73
  50. Landgren MB , Helmond FA , Engelen S . Tibolone relieves climacteric symptoms in highly symptomatic women with at least seven hot flushes and sweats per day . Maturitas . 2005;50:222–230
  51. Bruce D , Robinson J , Rymer J . Long-term effects of tibolone on the endometrium as assessed by bleeding episodes, transvaginal scan and endometrial biopsy . Climacteric . 2004;7:261–266
  52. Vogelvang TE , van der Mooren MJ , Mijatovic V . Hormone replacement therapy, selective estrogen receptor modulators, and tissue-specific compounds: cardiovascular effects and clinical implications . Treat Endocrinol . 2004;3:105–115
  53. Devogelaer JP . A review of the effects of tibolone on the skeleton . Expert Opin Pharmacother . 2004;5:941–949

PII: S1028-4559(07)60005-9

doi:10.1016/S1028-4559(07)60005-9

Taiwanese Journal of Obstetrics and Gynecology
Volume 46, Issue 2 , Pages 121-126, June 2007

Article Tools